Relapsed Refractory Multiple Myeloma (RRMM), Carfilzomib Maintenance, Proteasome Inhibitors (PI), 1 prior line of therapy, Phase 2, No Maintenance
### Instruction:
Identify the study with the following condition. 
### Input:
Relapsed Refractory Multiple Myeloma (RRMM), Carfilzomib Maintenance, Proteasome Inhibitors (PI), 1 prior line of therapy, Phase 2, No Maintenance 
### Output:
Popular Name is MUK Five, Study ID is ISRCTN17354232